PMID- 29632589
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240313
IS  - 1758-3780 (Electronic)
IS  - 1758-3772 (Print)
IS  - 1758-3772 (Linking)
VI  - 12
IP  - 1
DP  - 2016 Mar
TI  - New Developments in the Treatment of Neuroendocrine Tumours - RADIANT-4, NETTER-1 
      and Telotristat Etiprate.
PG  - 44-46
LID - 10.17925/EE.2016.12.01.44 [doi]
AB  - Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms whose 
      incidence has increased significantly in recent years, and whose optimal 
      management remains controversial. We report the latest innovations in their 
      management, in particular the results of three trials concerning the use of the 
      mammalian target of rapamycin (mTOR) inhibitor, everolimus, in non-functional 
      NETs of lung/ gastrointestinal (GI) origin, the first randomised trial of 
      radiolabelled (177)Lu-DOTATATE in patients with mid-gut NETs, and the use of the 
      5-HT synthesis inhibitor, telotristat etiprate, in patients with the carcinoid 
      syndrome.
FAU - Sbardella, Emilia
AU  - Sbardella E
AD  - Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and 
      Metabolism, Churchill Hospital, University of Oxford, Oxford, UK.
FAU - Grossman, Ashley
AU  - Grossman A
AD  - Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and 
      Metabolism, Churchill Hospital, University of Oxford, Oxford, UK.
LA  - eng
PT  - Editorial
DEP - 20160315
PL  - England
TA  - Eur Endocrinol
JT  - European endocrinology
JID - 101574781
PMC - PMC5813460
OTO - NOTNLM
OT  - 177Lu-DOTATATE
OT  - 5-HT synthesis inhibitor
OT  - Neuroendocrine tumours
OT  - everolimus
OT  - telotristat etiprate
OT  - treatment
EDAT- 2016/03/01 00:00
MHDA- 2016/03/01 00:01
PMCR- 2016/03/01
CRDT- 2018/04/11 06:00
PHST- 2016/01/07 00:00 [received]
PHST- 2016/02/29 00:00 [accepted]
PHST- 2018/04/11 06:00 [entrez]
PHST- 2016/03/01 00:00 [pubmed]
PHST- 2016/03/01 00:01 [medline]
PHST- 2016/03/01 00:00 [pmc-release]
AID - 10.17925/EE.2016.12.01.44 [doi]
PST - ppublish
SO  - Eur Endocrinol. 2016 Mar;12(1):44-46. doi: 10.17925/EE.2016.12.01.44. Epub 2016 
      Mar 15.